Illustration: Victoria Ellis/Axios
Novo Nordisk is partnering with Septerna to develop oral pills for obesity and other cardiometabolic diseases, in a deal worth up to $2.2 billion.
Why it matters: The transaction further signals Big Pharma's interest in oral GLP-1s — which could be a cheaper and easier way to take the medicines.